UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation

Blood cancer journal (New York), 2022-01, Vol.12 (1), p.13-13, Article 13

2022

Volltextzugriff (PDF)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis

Journal of Immunotherapy and Precision Oncology, 2021-08, Vol.4 (3), p.129-141

2021

Volltextzugriff (PDF)

Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices

Annals of hematology, 2023-05, Vol.102 (5), p.985-993

Kuykendall, Andrew T.

2023

Volltextzugriff (PDF)

Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices

Annals of hematology, 2023-07, Vol.102 (7), p.1967-1967

Kuykendall, Andrew T.

2023

Volltextzugriff (PDF)

Interferons in the treatment of myeloproliferative neoplasms

Therapeutic advances in hematology, 2024-01, Vol.15, p.20406207241229588-20406207241229588

2024

Volltextzugriff (PDF)

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real‐world Implications

HemaSphere, 2022-10, Vol.6 (10), p.e778-n/a

2022

Volltextzugriff (PDF)

What’s in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia

Journal of the National Comprehensive Cancer Network, 2020-09, Vol.18 (9), p.1279-1284

2020

Volltextzugriff (PDF)

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

The Lancet (British edition), 2023-01, Vol.401 (10373), p.269-280

2023

Volltextzugriff (PDF)

Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians

Clinical lymphoma, myeloma and leukemia, 2024-08, Vol.24 (8), p.512-522

2024

Volltextzugriff (PDF)

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Annals of hematology, 2018-03, Vol.97 (3), p.435-441

2018

Volltextzugriff (PDF)

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

The New England journal of medicine, 2024-02, Vol.390 (8), p.723-735

2024

Volltextzugriff (PDF)

Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes

Hematology/oncology clinics of North America, 2021-04, Vol.35 (2), p.337-352

2021

Volltextzugriff (PDF)

Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera

Expert opinion on emerging drugs, 2021-07, Vol.26 (3), p.209-218

2021

Volltextzugriff (PDF)

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities

Annals of hematology, 2024, Vol.103 (1), p.117-123

2024

Volltextzugriff (PDF)

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations

Cancer, 2022-11, Vol.128 (21), p.3880-3887

2022

Volltextzugriff (PDF)

Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy

Expert opinion on pharmacotherapy, 2023-06, Vol.24 (9), p.1091-1100

2023

Volltextzugriff (PDF)

Disease‐related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates

Cancer, 2022-10, Vol.128 (19), p.3495-3501

2022

Volltextzugriff (PDF)

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO

Current hematologic malignancy reports, 2019-12, Vol.14 (6), p.543-549

2019

Volltextzugriff (PDF)

Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

American journal of hematology, 2022-01, Vol.97 (1), p.E7-E10

2022

Volltextzugriff (PDF)

PTPN11 mutations are associated with poor outcomes across myeloid malignancies

Leukemia, 2021-01, Vol.35 (1), p.286-288

2021

Volltextzugriff (PDF)

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

Annals of hematology, 2022, Vol.101 (1), p.139-146

2022

Volltextzugriff (PDF)

Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis

Blood, 2024-10

2024

Volltextzugriff (PDF)

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

American journal of hematology, 2024-06, Vol.99 (6), p.1040-1055

2024

Volltextzugriff (PDF)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

Cancers, 2020-08, Vol.12 (8), p.2278

2020

Volltextzugriff (PDF)

1 – 25 von 322

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(319)
Mit Volltextzugriff
(280)

Publikationsform

Artikel
(320)
Tagungsberichte
(2)

Sprache

Englisch
(322)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(22)

Menü

Weitere Dienste

Einstellungen

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis

Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices

Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices

Interferons in the treatment of myeloproliferative neoplasms

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real‐world Implications

What’s in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes

Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations

Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy

Disease‐related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO

Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

PTPN11 mutations are associated with poor outcomes across myeloid malignancies

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

Suchergebnisse filtern